Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer

REFERENCES

• Navari RM. Pharmacological management of chemother-apy-induced nausea and vomiting: focus on recent develop-ments. Drugs. 2009; 69 (5): 515–33
   PubMed Web of Science ®Google Scholar
• U.S.DEPARTMENT OF HEALTH AND HUMAN SERV-ICES, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 29, 2009. http://ctep.cancer.gov/protocolDe-velopment/electronic_applications/ctc.htm#ctc_v40
   Google Scholar
• Warr DG. Chemotherapy- and cancer -related nausea and vomiting. Curr Oncol. 2008; 15 (Supplement 1): S4–9
   Google Scholar
• Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13 (2): 97–103.
   PubMed Web of Science ®Google Scholar
• Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13 (2): 104–08.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2005; 13: 117–121
   PubMed Web of Science ®Google Scholar
• Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP et al. Chemotherapy-Induced Nau-sea and Vomiting. Clin J Oncol Nurs. 2002; 6 (2): 94–102
   PubMedGoogle Scholar
• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358 (23): 2482–94.
   PubMed Web of Science ®Google Scholar
• Yamada T, Tanaka N, Yokoi K, Ishikawa N, Seya T, Horiba K et al. Substance P and anticancer drug-induced emesis. Gan To Kagaku Ryoho. 2007; 34 (6): 903–06
   PubMedGoogle Scholar
• WHO handbook for reporting results of Cancer Treat-ment. WHO offset publication No 48 Neoplasma. 1980; 20: 37–46
   Google Scholar
• NCI Common Toxicity Criteria. National Cancer Institute, Division of Cancer Treatment. 1988
   Google Scholar
• Franklin HR, Simonetti GPC, Dubbelman AC, ten Bokkel Huinink WW, Taal BG, Wigbout G et al. Toxicity grading sys-tems. Ann Oncol. 1994; 5: 113–17
   PubMed Web of Science ®Google Scholar
• Lohr L. Chemotherapy - induced nausea and vomiting. Cancer J 2008; 14 (2): 85–93
   PubMed Web of Science ®Google Scholar
• Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007; 12 (9): 1143–50
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al. A proposal for classifying the acute emeto-genicity of cancer chemotherapy. J Clin Oncol. 1997; 15: 103–109
   Google Scholar
• Multinational Association of Supportive Care in Cancer - Antiemetic Guidelines-. March 2008. http://data.mem-berclicks.com/site/mascc/MASCC_Guidelines_Update.pdf
   Google Scholar
• Relling MV, Mu!hem RK, Fairclough D, Baker D, Pui CH. Chlorpromazine with and without lorazepam as antiemetic ther-apy in children receiving uniform chemotherapy. J Pediatr. 1993; 123: 811–16
   PubMed Web of Science ®Google Scholar
• Nahata MC, Ford C, Ruymann FB. Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. J Clin Pharm Ther. 1992; 17: 121–23
   PubMed Web of Science ®Google Scholar
• Howrie DL, Felix C, Wollman M, Juhl RP, Blatt J. Meto-clopramide as an antiemetic agent in pediatric oncology patients. Drug Intell Clin Pharm. 1986; 20 (2): 122–4
   PubMedGoogle Scholar
• Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008; 5 (1): 32–43
   PubMedGoogle Scholar
• Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007; 61 (2): 162–75
   PubMed Web of Science ®Google Scholar
• Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow R, Warr D et al. Antiemetics in children receiving chemotherapy. Support Care Cancer. 2005; 13 (2): 129–31
   PubMed Web of Science ®Google Scholar
• Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs. 2001; 3 (6): 441–79
   PubMedGoogle Scholar
• Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004; 9 (6): 673–86.
   PubMed Web of Science ®Google Scholar
• Cappelli C, Ragni G, De Pasquale MD, Gonfiantini M, Russo D, Clerico A. Tropisetron: optimal dosage for children in prevention of chemotherapy-induced vomiting. Pediatr Blood Cancer. 2005; 45 (1): 48–53
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al. A phase III, double-blind, random-ized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441–9.
   Google Scholar
• Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10 (2): 115–24
   Google Scholar
• Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009; 10 (4): 629–44
   PubMed Web of Science ®Google Scholar
• Hasler SB, Hirt A, Ridolfi Luethy A, Leibundgut KK, Am-mann RA. Safety of ondansetron loading doses in children with cancer. Support Care Cancer. 2008; 16 (5): 469–75.
   PubMed Web of Science ®Google Scholar
• Hickock JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 anti-emetics. Cancer. 2003; 97: 2880-86
   Google Scholar
• Girish C, Manikandan S. Aprepitant: a substance P an-tagonist for chemotherapy induced nausea and vomiting. Indian J Cancer. 2007; 44 (1): 25–30
   PubMedGoogle Scholar
• Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. JClin Oncol. 2001; 19: 1759–67
   Google Scholar
• Poli-Bigelli S, Rodriguez-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard anti-emetic therapy im-proves control of chemotherapy-induced nausea and vomiting. Cancer. 2003; 97: 3090–98
   Google Scholar
• Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH et al. Comparison of L-758,298, a pro-drug for the selective neurokinin-1 antagonist L-754,030, with ondasentron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001; 37: 835–42
   Google Scholar
• Sarcev T, Secen N, Zaric B, Milovancev A. Aprepitant—where do we stand in the control of chemotherapy-induced nau-sea and vomiting? J BUON. 2008; 13 (3): 333–39
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B, Carides AD, Guogu-ang-Ma J, Elmer M et al. The oral NK-1 antagonist, aprepitant, given with standard anti-emetics provides protection against nau-sea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analyses of two randomized, placebo-controlled Phase III clinical trials. Eur J Cancer. 2004; 40: 403–10
   Google Scholar
• Herrstedt J, Dombemowsky P. Anti-emetic therapy in can-cer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007; 101 (3): 143–50
   PubMed Web of Science ®Google Scholar
• Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy -induced nausea and vomit-ing. Expert Rev Anticancer Ther. 2004; 4 (5): 715–24
   PubMedGoogle Scholar
• Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua Vet al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, dou-ble-blind, placebo-controlled study of efficacy and tolerability. Pe-diatr Blood Cancer. 2009; 52 (2): 242–7
   Google Scholar
• Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer. 2009; 17 (6): 701–6
   PubMed Web of Science ®Google Scholar
• Grunberg SM. Antiemetic activity of corticosteroids in Patients receiving cancer chemotherapy: dosing, efficacy, and tol-erability analysis. Ann Oncol. 2007; 18 (2): 233–40
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology. 2007; 21 (8): 946–53
   PubMed Web of Science ®Google Scholar
• Davis M, Maida V, Daeninck P, Pergolizzi J. The emerg-ing role of cannabinoid neuromodulators in symptom manage-ment. Support Care Cancer. 2007; 15: 63–71
   PubMed Web of Science ®Google Scholar
• Slatkin NE. Cannabinoids in the treatment of chemother-apy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007; 5 issue>(5 Suppl 3): 1–9
   Google Scholar
• Reindl TK, Geilen W, Hartmann R, Wiebelitz KR, Kan G, Wilhelm I et al. Acupunture against chemotherapy-induced nau-sea and vomiting in pediatric oncology. Interim results of a mul-ticenter crossover study. Support Care Cancer. 2006; 14: 172–76
   Google Scholar
• Bao T. Use of acupuncture in the control of chemother-apy-induced nausea and vomiting. J Natl Compr Canc Netw. 2009; 7 (5): 606–12
   PubMed Web of Science ®Google Scholar
• Richardson J, Smith JE, McCall G, Richardson A, Pilk-ington K, Kirsch I. Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. Eur J Cancer Care. 2007; 16 (5): 402–12.
   PubMed Web of Science ®Google Scholar